Heart Diseases
Heart Diseases
Search
Annual Results Press Conference
Boehringer Ingelheim presents the results of business development and gives an outlook for the coming year.
Early Access Treatments & Compassionate Use Programs
Explore how we facilitate patient access to investigational and/or unlicensed medicines through our individual requests and Compassionate Use programs
Our partners Bioveta
Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
Advancing health equity for rural doctors in Mexico
Our virtual sales team helps doctors stay informed through digital education about the latest treatments, regardless of their location
Corporate Profile
Corporate Profile
Cancer
Cancer
Pet parasites are still here. What's the risk?
What's the risk of pet parasites? They’re a growing challenge due to climate change. Check how to protect your dog and cat from fleas, ticks and more.
Animal Health Partnering Contacts
Partnership and diversity of thought are powerful drivers of innovation. If you have a project you would like to discuss please reach out to us.
Retinal Diseases
Retinal Diseases
Data Career
Data science at Boehringer Ingelheim is more than just solving fascinating problems. A chance to provide innovative solutions that bring value and hope to people.
Life forward
In everything we do we can shape and influence the future for the better: Learn more about “Life forward” and how our innovations improve lives.
The Research Process
The Research Process
Trailr2-cdh17-antibody-phase1-trial
Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
Partnering pet therapeutics
Learn more about our research focus and our most recent partnerships regarding pet therapeutics.
Outlook for Partnering in Animal Health 2024
Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
collaboration-proxygen-molecular-glue-degraders
Boehringer Ingelheim collaborates with Proxygen to explore molecular glue degraders – a novel approach to fight cancer.
Lameness horses collaboration Sleip app artificial intelligence
The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone.
Making sustainable medicines through eco-design
Our goal is to minimize the environmental footprint of our medicines through integration of eco-design and green chemistry across the entire lifecycle
biolabs-heidelberg
Boehringer Ingelheim supports the launch of BioLabs first European Location in Heidelberg.
Cardio-Renal-Metabolic
Cardio-Renal-Metabolic Therapeutic Area
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award
SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU
Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
Partnership for new liver disease treatments with Ribo
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases